Skip to main content

Table 1 Baseline characteristics of included patients

From: Phospholipase A2 group IIA correlates with circulating high-density lipoprotein cholesterol and modulates cholesterol efflux possibly through regulation of PPAR-γ/LXR-α/ABCA1 in macrophages

  Low HDL-C (< 1.04 mmol/L) High HDL-C (≥ 1.04 mmol/L) p value
Male, n(%) 44 (80%) 50 (66%) 0.513
Age(year) 63.69 ± 11 63.03 ± 9.58 0.71
Hypertension, n(%) 33 (58%) 39 (51%) 0.419
Diabetes, n(%) 19 (35%) 18 (24%) 0.244
Smoking, n(%) 17 (31%) 22 (29%) 0.961
Gout, n(%) 2 (4%) 2 (3%) 0.56
LDL-C (mmol/L) 1.93 ± 0.79 2.67 ± 1.08 0.000
TC (mmol/L) 3.45 ± 0.87 4.85 ± 1.36 0.000
TG (mmol/L) 1.27 ± 0.48 1.79 ± 1.52 0.007
sPLA2 IIA (pg/mL) 5836.92 (3797.444–9198.456) 7477.828(5291.296–11,965.632) 0.004
Statin treatment, n(%) 32 (58%) 39 (51%) 0.548
hsCTNI level (ng/mL) 0.005 (0.002–0.011) 0.003 (0.001–0.009) 0.181
Unstable angina, n(%) 24 (44%) 21 (28%) 0.086
History of stent implantation, n(%) 10 (18%) 12 (19%) 0.901
  1. HDL-C high-density lipoprotein cholesterol, hsCTNI hypersensitive cardiac troponin I, LDL-C low density lipoprotein-cholesterol, sPLA2 IIA secretory phospholipase A2 type IIA, TC total cholesterol, TG triglyceride